Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents

Headache The Journal of Head and Face Pain 2026 Open access

Read full text
Authors: Konstantinos Tourlas, Sruthi Ilangovan, Chelsea White, Samantha Lee Irwin, Sara Pavitt
DOI: 10.1111/head.70033
Cited by: 1
References: 29

Abstract

OBJECTIVE: This study aims to evaluate the tolerability and effectiveness of the off-label use of rimegepant as acute migraine treatment in adolescents. BACKGROUND: Calcitonin gene-related peptide (CGRP) levels are elevated during migraine attacks. Gepants, oral CGRP receptor antagonists, have demonstrated effectiveness as acute and preventive migraine treatment in adults. They are generally well tolerated with limited side effects. Their use for migraine is approved by the United States Food and Drug Administration (FDA) in adults; however, data on their use in adolescents remain limited. METHODS: This is a retrospective chart review of pediatric patients

Fields of Study & Subjects

Migraine and Headache Studies Traumatic Brain Injury Research Neurological Disorders and Treatments

Publication details

Journal / source
Headache The Journal of Head and Face Pain
Publisher
Wiley
Volume
66
Issue
4
Pages
829–834
Publication date
6 February 2026
Language
EN